Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Myalgia
Clinical narrative: Patient experienced minor symptoms after first and second dose of Moderna, such as body aches; COVID-19 infection: Yes. Patient had COVID-19 a month ago, that was the reason why she was taking monoclonal antibodies; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (COVID-19 infection: Yes. Patient had COVID-19 a month ago, that was the reason why she was taking monoclonal antibodies) and MYALGIA (Patient experienced minor symptoms after first and second dose of Moderna, such as body aches) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In April 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2022, the patient experienced COVID-19 (COVID-19 infection: Yes. Patient had COVID-19 a month ago, that was the reason why she was taking monoclonal antibodies). On an unknown date, the patient experienced MYALGIA (Patient experienced minor symptoms after first and second dose of Moderna, such as body aches). The patient was treated with MONOCLONAL ANTIBODIES, GRANULOCYTE (intravenous) for COVID-19, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19 infection: Yes. Patient had COVID-19 a month ago, that was the reason why she was taking monoclonal antibodies) and MYALGIA (Patient experienced minor symptoms after first and second dose of Moderna, such as body aches) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported as HCP was calling regarding a patient who wanted to receive Moderna booster vaccine but has experienced a severe allergic reaction a month ago to monoclonal antibodies. Patient's weight and height were unknown. Patient did not experience a severe allergic reaction to Moderna Vaccines.   Symptoms of the severe allergic reaction to monoclonal antibodies included shortness of breath, tachycardia, severe joint pain, temporally paralyses of her legs. This allergic reaction started 10 minutes after treatment started. Exact date is unknown but it was a month ago. Monoclonal antibodies were provided as an IV infusion. She was hospitalized but discharge the same day. It was the first time that the patient experience an event like this. She is totally recovered at the moment.   No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Consent to follow-up with Safety Team was reported as Yes. E-mail address confirmed.  Company comment:  This case concerns a 40-year-old female patient with no medical history reported, who experienced the unexpected non-serious, event of COVID-19 (adverse event of special interest), approximately 9 months after receiving the second dose of mRNA-1273 vaccine. The patient was treated with monoclonal antibodies for COVID-19. Outcome was resolved. COVID-19 pandemic is a confounder for the event COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-495716 (Patient Link).; Sender's Comments: This case concerns a 40-year-old female patient with no medical history reported, who experienced the unexpected non-serious, event of COVID-19 (adverse event of special interest), approximately 9 months after receiving the second dose of mRNA-1273 vaccine. The patient was treated with monoclonal antibodies for COVID-19. Outcome was resolved. COVID-19 pandemic is a confounder for the event COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.